Brookline Capital Management Estimates Genelux Q1 Earnings

Genelux Co. (NASDAQ:GNLX) – Investment analysts at Brookline Capital Management issued their Q1 2025 earnings per share estimates for shares of Genelux in a research report issued on Tuesday, March 25th. Brookline Capital Management analyst K. Dolliver forecasts that the company will post earnings of ($0.20) per share for the quarter. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.16) EPS and Q4 2025 earnings at ($0.16) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Genelux in a research note on Tuesday. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $18.25.

Genelux Price Performance

Shares of GNLX opened at $3.03 on Thursday. Genelux has a 1 year low of $1.60 and a 1 year high of $6.50. The company has a 50 day simple moving average of $4.05 and a two-hundred day simple moving average of $3.09. The firm has a market cap of $104.65 million, a P/E ratio of -3.19 and a beta of -1.41.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd bought a new stake in Genelux in the third quarter worth $59,000. Geode Capital Management LLC increased its holdings in shares of Genelux by 39.7% in the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock worth $749,000 after buying an additional 89,854 shares during the last quarter. Apollon Wealth Management LLC raised its position in shares of Genelux by 20.4% during the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after buying an additional 2,857 shares in the last quarter. D.A. Davidson & CO. bought a new position in shares of Genelux in the 4th quarter valued at about $51,000. Finally, LifeSteps Financial Inc. grew its position in Genelux by 11.1% in the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock worth $205,000 after acquiring an additional 8,715 shares in the last quarter. 37.33% of the stock is currently owned by institutional investors.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.